Your browser is no longer supported. Please, upgrade your browser.
DVAX Dynavax Technologies Corporation monthly Stock Chart
DVAX [NASD]
Dynavax Technologies Corporation
Index- P/E- EPS (ttm)-3.11 Insider Own0.36% Shs Outstand41.12M Perf Week-19.37%
Market Cap614.33M Forward P/E- EPS next Y-1.29 Insider Trans0.00% Shs Float38.36M Perf Month-30.51%
Income-106.80M PEG- EPS next Q-0.63 Inst Own83.70% Short Float18.28% Perf Quarter-34.53%
Sales4.10M P/S149.84 EPS this Y5.90% Inst Trans0.88% Short Ratio7.51 Perf Half Y-39.09%
Book/sh3.55 P/B4.21 EPS next Y50.40% ROA-63.10% Target Price36.00 Perf Year-24.39%
Cash/sh4.77 P/C3.13 EPS next 5Y- ROE-78.00% 52W Range15.52 - 32.49 Perf YTD-38.16%
Dividend- P/FCF- EPS past 5Y14.10% ROI- 52W High-54.02% Beta2.42
Dividend %- Quick Ratio6.90 Sales past 5Y-29.90% Gross Margin- 52W Low-3.74% ATR1.24
Employees234 Current Ratio6.90 Sales Q/Q-69.60% Oper. Margin- RSI (14)26.18 Volatility6.92% 5.53%
OptionableYes Debt/Eq0.00 EPS Q/Q39.80% Profit Margin- Rel Volume1.80 Prev Close16.08
ShortableYes LT Debt/Eq0.00 EarningsMay 05 BMO Payout- Avg Volume933.17K Price14.94
Recom2.30 SMA20-26.88% SMA50-20.78% SMA200-37.75% Volume1,676,555 Change-7.09%
Apr-28-16Downgrade RBC Capital Mkts Outperform → Sector Perform $48 → $17
Apr-27-16Downgrade JP Morgan Overweight → Neutral
Nov-30-15Initiated RBC Capital Mkts Outperform $48
Nov-25-13Upgrade MLV & Co Hold → Buy $1.50 → $5
Feb-25-13Downgrade MLV & Co Buy → Hold
Nov-16-12Reiterated MLV & Co Buy $10 → $7.50
Jan-04-12Initiated MLV & Co Buy $8
Nov-09-10Reiterated Wedbush Outperform $6 → $8
Nov-08-10Initiated Jefferies Buy $4
May-13-10Upgrade Wedbush Neutral → Outperform $2.60 → $6
Mar-20-09Initiated Wedbush Morgan Buy $1.20
Oct-22-08Downgrade Oppenheimer Outperform → Perform
May-19-08Reiterated Susquehanna Financial Positive $7 → $5
May-19-08Downgrade Bear Stearns Outperform → Peer Perform
Mar-18-08Downgrade Merriman Curhan Ford Buy → Neutral
Feb-22-08Upgrade Oppenheimer Perform → Outperform $8.50
Oct-03-07Initiated Credit Suisse Outperform $8
Jun-06-07Initiated Susquehanna Financial Positive
Feb-26-07Downgrade JMP Securities Mkt Outperform → Mkt Perform
May-03-16 08:40AM  Does This Upstart Pose a Threat to GlaxoSmithKline? at Motley Fool
Apr-29-16 02:11PM  ETFs with exposure to Dynavax Technologies Corp. : April 29, 2016 at Capital Cube -6.39%
Apr-28-16 08:19AM  Dynavax Technologies Corp. breached its 50 day moving average in a Bearish Manner : DVAX-US : April 28, 2016 at Capital Cube -5.40%
06:16AM  Dynavax downgraded by RBC Capital Mkts Briefing.com
Apr-27-16 04:19PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -11.68%
02:04PM  Why Dynavex Technologies Shares Are Crashing Today at Motley Fool
12:01PM  Why Traders Are Selling These Five Tanking Stocks? at Insider Monkey
07:00AM  Dynavax Receives Notification of PDUFA Extension for HEPLISAV-B to December 15, 2016 Marketwired
Apr-21-16 10:43AM  3 Biotech Stocks I'd Buy Right Now at Motley Fool
Apr-19-16 04:31PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stat
Apr-18-16 04:02PM  Dynavax Presents Pivotal Phase 3 Data Showing HEPLISAV-B(TM) Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B(R) Marketwired
04:02PM  Dynavax Presents Encouraging Data From Clinical Trial of Immuno-Oncology Product Candidate, SD-101 Marketwired
Apr-12-16 09:02AM  3 Biotech Stocks to Buy in April at Motley Fool
Apr-09-16 03:24PM  Here's Why Dynavax Technologies Corporation's Stock Gained 14.5% In March at Motley Fool
Apr-08-16 10:05AM  How Risky Is Dynavax Technologies Stock? at Motley Fool
Apr-05-16 03:37PM  Dynavax Technologies Corp. Value Analysis (NASDAQ:DVAX) : April 5, 2016
Apr-04-16 07:00PM  Lightning Round: This group cannot be bought at CNBC +6.25%
08:04AM  Dynavax Technologies Corp. breached its 50 day moving average in a Bullish Manner : DVAX-US : April 4, 2016
07:00AM  Dynavax to Present Data From Pivotal Phase 3 HEPLISAV-B(TM) Trial Marketwired
Mar-31-16 04:16PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits +6.59%
03:02PM  Here's Why Dynavax Technologies (DVAX) Stock is Climbing Today at TheStreet
Mar-30-16 05:13PM  Dynavax Announces FDA Acceptance for Review of Biologics License Application and PDUFA Action Date for HEPLISAV-B(TM) Marketwired
Mar-17-16 07:00AM  Dynavax Announces Data Presentations at AACR Annual Meeting Marketwired
Mar-16-16 12:50PM  4 More Key FDA Decisions in March at 24/7 Wall St.
Mar-14-16 03:30PM  ETFs with exposure to Dynavax Technologies Corp. : March 14, 2016
10:13AM  Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-12-16 01:04PM  DYNAVAX TECHNOLOGIES CORP Financials
09:47AM  Dynavax Technologies Corporation's Stock Got Crushed in February -- Time to Buy? at Motley Fool
Mar-09-16 04:04PM  The 52-Week Low Club for Wednesday at 24/7 Wall St.
Mar-08-16 04:56PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -6.54%
04:49PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 10-K, Annual Report
07:21AM  Dynavax Technologies reports 4Q loss
07:00AM  Dynavax Reports Fourth Quarter and Year End 2015 Financial Results Marketwired
Mar-02-16 04:05PM  Dynavax to Participate in the Cowen and Company 36th Annual Health Care Conference
Feb-23-16 12:30PM  Dynavax, GlaxoSmithKline Battling In Same Industry: Who Will Win? -7.86%
Feb-17-16 07:00AM  Dynavax to Participate in 2016 RBC Capital Markets Global Healthcare Conference Marketwired
Feb-16-16 08:30AM  Qualitative Analysis Highlights These Top Stocks Cempra, Dynavax Technologies, INSYS Therapeutics, and Radius Health Accesswire +5.11%
Feb-09-16 05:01PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Change in Directors or Principal Officers
Jan-25-16 08:05AM  Dynavax Technologies Corp. breached its 50 day moving average in a Bullish Manner : January 25, 2016
08:00AM  Strength Seen in Dynavax (DVAX): Stock Gains 11.1%
Jan-20-16 05:02PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex +9.30%
04:13PM  Dynavax, AstraZeneca Amend Deal for Asthma Candidate
Jan-19-16 04:00PM  Dynavax and AstraZeneca Amend Their Agreement for Asthma Drug Candidate Marketwired
Jan-14-16 09:30AM  The Zacks Analyst Blog Highlights: Baxalta, Juno, Horizon Pharma, AbbVie and Dynavax
Jan-13-16 04:14PM  Biotech Stock Roundup: Baxalta - Shire to Combine, JPM Healthcare Conference in Focus
Jan-12-16 08:06AM  Dynavax Technologies Corp. breached its 50 day moving average in a Bearish Manner : January 12, 2016 -5.51%
08:02AM  These Biotech Stocks Could Double in 2016 at Motley Fool
Jan-11-16 04:43PM  Dynavax to Present at J.P. Morgan 34th Annual Healthcare Conference Marketwired -6.57%
Jan-08-16 02:40PM  Dynavax's Heplisav-B Tops GlaxoSmithKline's Engerix-B -9.80%
08:15AM  Dynavax Technologies (DVAX) Catches Eye: Stock Up 40.2%
Jan-07-16 04:22PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits +40.23%
04:20PM  Why #JPM16 matters: Biotechs open news spigots ahead of big conference at bizjournals.com
03:40PM  Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial at Investor's Business Daily
02:51PM  Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial at Investor's Business Daily
01:55PM  Dynavax Soars on Positive Late Stage Results
01:38PM  Why Are Investors Bullish On These Five Stocks On Thursday? at Insider Monkey
09:49AM  Dynavax Technologies Corporation's Stock Bolts Higher on Positive Clinical Update at Motley Fool
07:44AM  Dynavax's hep B vaccine meets goals in late-stage study
07:16AM  Dynavax's hep B vaccine meets main goals in late-stage study
07:00AM  Dynavax Reports Top Line Results of Phase 3 HEPLISAV-B(TM) Study Marketwired
Jan-06-16 05:04PM  Dynavax to Host Webcast Conference Call Tomorrow to Review HEPLISAV-B(TM) Phase 3 Clinical Data Marketwired -8.55%
Dec-29-15 08:12AM  Dynavax Technologies Corp. breached its 50 day moving average in a Bearish Manner : December 29, 2015
Dec-16-15 10:03AM  Dynavax Technologies Corp. Value Analysis (NASDAQ:DVAX) : December 16, 2015
Dec-15-15 01:00PM  Dynavax Technologies Corp. Earnings Analysis: Q3, 2015 By the Numbers +5.25%
09:03AM  Dynavax Technologies Corp. breached its 50 day moving average in a Bearish Manner : December 15, 2015
Dec-05-15 05:30PM  Dynavax Presents Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, at ASH Annual Meeting Marketwired
Dec-02-15 08:31AM  What Do Hedge Funds Think of Achillion Pharmaceuticals, Inc. (ACHN)? at Insider Monkey
Dec-01-15 11:14AM  Hedge Funds Are Buying Dynavax Technologies Corporation (DVAX) at Insider Monkey
Nov-30-15 04:00PM  Dynavax Announces Presentation of Clinical Data at ASH Annual Meeting Marketwired +6.33%
Nov-28-15 03:01PM  What Do Hedge Funds Think of Alamos Gold Inc (AGI)? at Insider Monkey
Nov-21-15 01:15PM  JPMorgan Likes These 5 Biotech Stocks at TheStreet
Nov-19-15 08:29AM  Dynavax Technologies Corp. breached its 50 day moving average in a Bullish Manner : November 19, 2015
Nov-12-15 04:06PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
Nov-05-15 04:43PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
07:29AM  Dynavax Technologies reports 3Q loss
07:00AM  Dynavax Reports Third Quarter 2015 Financial Results Marketwired
Nov-01-15 07:01AM  5 Top Stocks to Buy In November at Motley Fool
Oct-30-15 08:19AM  Why biotech could be on the verge of a rebound
Oct-14-15 09:47AM  Pullbacks Make Better Buys Of Amgen and Four Biotech Stocks at Forbes
Oct-12-15 02:50PM  Qiagen Poised on Molecular Diagnostics, International Business
Oct-08-15 04:15PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab) Marketwired
Sep-24-15 12:34PM  ETFs with exposure to Dynavax Technologies Corp. : September 24, 2015
10:30AM  Dynavax Technologies Corp. breached its 50 day moving average in a Bearish Manner : September 24, 2015
Sep-16-15 03:25PM  1 Smart Way to Play the Biotech Bounce at Motley Fool
Sep-15-15 05:02PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events
Sep-14-15 07:24AM  Dynavax Technologies (DVAX) Shares March Higher, Can It Continue?
Sep-09-15 03:38PM  6 stocks to watch at MarketWatch
Sep-03-15 09:00AM  Dynavax to Participate in Two Upcoming Investor Conferences Marketwired
Aug-09-15 08:13PM  10-Q for Dynavax Technologies Corp. at Company Spotlight
Aug-07-15 04:19PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:09PM  Dynavax Technologies reports 2Q loss
04:01PM  Dynavax Reports Second Quarter 2015 Financial Results Marketwired
Jul-28-15 08:00AM  Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock Marketwired
Jul-22-15 04:08PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex +5.80%
08:15AM  Dynavax Prices Public Offering of Common Stock Marketwired
Jul-21-15 04:01PM  Dynavax Announces Proposed Public Offering of Common Stock Marketwired
Jul-09-15 04:22PM  DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial +8.27%
02:01PM  Why Shares in Dynavax Technologies Corp Are Soaring 10% Higher Today at Motley Fool
01:40PM  Trending Now: Dynavax Technologiesn
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. Its development programs focuses on vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The company's lead products include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, a C Class CpG TLR9 agonist for the treatment of cancer, which is in Phase I/II multicenter clinical trial. Its product portfolio also comprises AZD1419 for the treatment of asthma, which is in Phase II clinical trial; DV1179, a TLR7/9 inhibitor that is in Phase Ib/IIa for the treatment of autoimmune and inflammatory conditions; and DV281 and CpG-Nanoparticles, which are in preclinical studies for cancer immunotherapy. It has a research collaboration and license agreement with AstraZeneca AB to conduct a Phase IIa safety and efficacy trial of AZD1419 for the treatment of asthma; and strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Janssen RobertVice PresidentOct 08Buy23.341002,334100Oct 09 04:08 PM
Plotkin Stanley ADirectorAug 26Option Exercise11.501,00011,5001,000Aug 26 04:49 PM